Sanofi reports Q1 business EPS EUR 2.16, up 11.9% at CER

Business EPS was EUR 2.16, up 11.3% on a reported basis and 11.9% at CER, while IFRS EPS was EUR 1.60, down 0.6%. Reports Q1 IFRS net sales EUR 10.22B, up 5.5% at CER. CEO Paul Hudson said: "We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses. Dupixent continues its compelling performance and is on track to achieve its EUR 10 billion sales objective for this year. The unique product profile of Dupixent was further underscored by highly positive pivotal results in uncontrolled chronic obstructive pulmonary disease, which we are looking forward to discusswith regulators. We are also advancing our early-to-mid stage pipeline and plan to feature several promising candidates at upcoming R&D investor events. For the remainder of the year, we are confident in our business outlook, while navigating the impact from generic versions of Aubagio, our last meaningful patent expiry this decade, with generics entering the U.S. market at the end of Q1. With the U.S. launch of ALTUVIIIO now underway and the anticipated roll-out of Beyfortus in time for the RSV season later this year, we keep executing on our Play to Win growth strategy."